Ahead of results, Kalkine looks at how costly late-stage trials for Amgen's monthly obesity shot MariTide weigh on the outlook.
Recap by typeshit. Full story at Kalkine Media.
The chain says it is exploring concepts including grilled items aimed at GLP-1 users, a sign of how the drugs are shifting food businesses.
A short post says demand for GLP-1s, psychedelics and testosterone is meeting commercial interests, calling it a big shift.
A beauty take that waves off pricey LA peptide and salmon sperm serums, saying better anti-aging habits are found closer to home.
LLY reached a fresh record while many tech stocks keep swinging, and the post weighs whether investors should take some profits.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Loading…